spherix global insights services Services
Special Report: Multi-Specialty Impact of COVID-192020-05-13T19:00:03+00:00

Special Report: Multi-Specialty Impact of COVID-19

To help stakeholders gauge the degree of impact that the COVID-19 pandemic is having on physicians, Spherix will begin ongoing coverage included in the Special Report: Multi-Specialty Impact of COVID-19 series. A subscription to the Special Report will include a weekly deliverable of data collected from the prior week, with coverage beginning March 20 and continuing through mid-May.

Specialty reports are available for dermatology, gastroenterology, nephrology, neurology, and rheumatology. Each wave will consist of feedback gathered from 250 specialists (~50 per specialty above), geographically dispersed. A deeper dive into each specialty is available upon request.

Content Categories Include:

Impact on Practice

  • Financial impact on practice
  • Level of concern for patients
  • Covering for partners
  • Impact on clinical trial involvement
  • Policies against travel/meetings
  • Conference cancellations
  • Restricting non-essential visits (industry, etc.)
  • Implementation of telemedicine
  • Preparedness for widespread local outbreak
  • Appointment cancellations
  • Rescheduling routine visits
  • Overall impact to patient flow


  • Belief in being able to “flatten the curve”
  • Satisfaction with how government handling
  • Impact on supply chain for medication access
  • Access to care from ER/ED or urgent care facilities
  • Expected timeline for resolution?
  • Government performance
  • Willingness to try new products currently
  • Willingness to initiate patients on therapy or change treatment
  • Familiarity and anticipated utility of Gilead’s remdesivir against COVID-19

Interaction with Industry

  • Restrictions of in-person contact
  • Recent industry contact methods
  • Pharmaceutical industry support during outbreak
  • Pharmaceutical company most active in addressing COVID-19 at national level / within personal practice


  • Number requesting test
  • Level of risk among requesting patients
  • Number tested
  • Number of positive/negative among those tested
  • Logistics of testing
  • Barriers to testing

Information on COVID-19

  • Source(s) being used for your own information
  • Most valuable information sources
  • Contact with state health department
  • How informed physicians feel about COVID-19 testing, guidelines, and treatment


  • Percent at risk
  • Characteristics of most at risk
  • How well informed about true risks


  • Specialty, patient volume, practice type, practice location, infusion capabilities, and clinical trial participation
  • Nearby outbreak and related restrictions
  • Personal travel to EU or China in past three months

Specialty specific

  • In immune, use of IL-6 inhibitors
  • In MS, switching from or delaying next doses of immunosuppressant DMTs
  • In migraine, use of newly approved therapy or anti-CGRP monoclonal antibodies
  • In nephrology, impact in dialysis units

Get In Touch With Us

*Required fields

Read the Latest

Amid the COVID-19 Pandemic, Neurologists in Canada Report Pulling Back from EMD Serono’s Mavenclad and Sanofi Genzyme’s Lemtrada, While Roche’s Ocrevus Stalls, According to Spherix Global Insights

May 27, 2020|

Use in treatment-naïve patients drives recent growth of Biogen’s Tecfidera and Genzyme’s Aubagio in Canada, as reported switch share has remained flat over the past year – reflecting the continued shift in using established oral agents earlier in the multiple sclerosis treatment algorithm

Load More Posts